A new report in Lancet Oncology offers guidance on which patients with prostate cancer who are initially treated with radiotherapy and 6 months of neoadjuvant androgen deprivation therapy (ADT) are at relatively high and relatively low levels of risk for prostate cancer-specific mortality.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, androgen deprivation, cancer-specific, marker, mortality, neoadjuvant, progression, PSA, radiation, surrogate | 2 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site
